| Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169) |
|---|
| 02/23/2005 | CN1190215C Chinese herbal medicine for treating rheumatism |
| 02/23/2005 | CN1190213C External used Chinese medicine adhesive plaster for curing appendicitis |
| 02/23/2005 | CN1190208C Medical salt for treating rheumatism |
| 02/23/2005 | CN1190196C Anti-inflammation and antibiotic external synthesized medicine, soluble hemostatic gauze and its processing |
| 02/22/2005 | US6858739 Indole and benzimidazole 15-lipoxygenase inhibitors |
| 02/22/2005 | US6858642 For use in pharmaceutical, skin-protective and cosmetic formulations |
| 02/22/2005 | US6858628 Substituted cyclic amine metalloprotease inhibitors |
| 02/22/2005 | US6858627 For therapy of inflammatory, allergic, or proliferative conditions |
| 02/22/2005 | US6858626 Cyclic hydroxamic acid as metalloproteinase inhibitors |
| 02/22/2005 | US6858624 Comprises 5,8,14-triazatetracyclo(10.3.1.0.0)-hexadeca-2(11),3,5,7,9-penaene groups; for reducing drug addiction, treating Alzheimer's/Parkinson's diseases, and other nervous system disorders |
| 02/22/2005 | US6858620 For therapy of male erectile dysfunction; female arousal disorder |
| 02/22/2005 | US6858597 Halogenated sulphamate-, phosphonate-, thiophosphonate-, sulphonate- and sulphonamide- compounds as inhibitors of steroid sulphatase |
| 02/22/2005 | US6858596 Aqueous suspension of Fluticasone furoate; respiratory tract disorders; asthma, COPD; antiinflammatory, antiallergen; nasal inhaler |
| 02/22/2005 | US6858593 Composition in which the crystal lattice is stabilised by the presence of a guest molecule, characterised in the crystalline composition is of space group P212121 having unit cell dimensions of about 7. 6+-0.6 Angstrom , 12.7+-0.7 Angstrom , |
| 02/22/2005 | US6858420 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 02/22/2005 | CA2236256C A pharmaceutical composition for the treatment of autoimmune diseases |
| 02/22/2005 | CA2129039C Tri-substituted phenyl derivatives as phosphodiesterase inhibitors |
| 02/21/2005 | CA2477901A1 Cyanoacrylate compositions containing anti-microbial agent |
| 02/17/2005 | WO2005014600A1 Antagonists of mcp-1 function and methods of use thereof |
| 02/17/2005 | WO2005014584A1 3-(indol-1-yl)-4-(indol-3-yl)-pyrrole-2,5-diones,3-(benzimidazol-1-yl)-4-(indol-3-yl)-pyrrole-2,5-diones, and 3-(indolin-1-yl)-4-(indol-3-yl)-pyrrole-2,5-diones; their preparation and use as modulators of apoptosis |
| 02/17/2005 | WO2005014580A1 Pyridyl piperazinyl ureas |
| 02/17/2005 | WO2005014579A1 Imidazol derivatives of piperdine as histamine antagonists |
| 02/17/2005 | WO2005014576A1 Isoquinolinone derivative, process for producing the same and use thereof |
| 02/17/2005 | WO2005014567A1 Mycophenolic acid bismuth salt |
| 02/17/2005 | WO2005014558A1 Condensed pyramidine compounds as inhibitors of voltage-gated ion channels |
| 02/17/2005 | WO2005014556A1 2-aminopyrimidine derivatives |
| 02/17/2005 | WO2005014550A1 3- aminocarbonyl, 6-phenyl substituted pyridine-1-oxides as p38 kinase inhibitors |
| 02/17/2005 | WO2005014529A1 2- adamantyl derivatives as p2x7 receptor antagonists. |
| 02/17/2005 | WO2005013997A1 Spiro-substituted tetrahydroquinazolines as corticotropin releasing factor (cfr) antagonists |
| 02/17/2005 | WO2005013989A1 Use of indazole derivatives for the treatment of neuropathic pain |
| 02/17/2005 | WO2005013966A1 Macrophage activation inhibitor |
| 02/17/2005 | WO2005013938A1 Process for producing drug ultramicroparticle and apparatus therefor |
| 02/17/2005 | WO2005013691A1 Use of boranocarbonates for the therapeutic delivery of carbon monoxide |
| 02/17/2005 | WO2004087173B1 Formulations for mediating inflammation and for reducing blood cholesterol |
| 02/17/2005 | WO2003099192A8 Bis-aromatic alkanols |
| 02/17/2005 | WO2003080568A3 Probucol derivatives |
| 02/17/2005 | WO2003025131A3 Protein modification and maintenance molecules |
| 02/17/2005 | WO2002074913A3 Nucleic acid-associated proteins |
| 02/17/2005 | US20050038505 Drug-delivery endovascular stent and method of forming the same |
| 02/17/2005 | US20050038259 Elastase release inhibitors; such as 19-(1H-tetrazol-5-yl)nonadec-6-en-5-ol |
| 02/17/2005 | US20050038243 2, 4-pyrimidinediamine compounds and their uses |
| 02/17/2005 | US20050038120 for inhibiting or modulating nitric oxide synthesis; nitric oxide synthase inhibitor; rheumatoid and osteoarthritis; inflammatory bowel disease; asthma |
| 02/17/2005 | US20050038119 for treatment of neutrofil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bollous pemphigo, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis; prevention and treatment of damages caused by ischemia and reperfusion |
| 02/17/2005 | US20050038118 Treatment |
| 02/17/2005 | US20050038104 Substitute benzothiophene compounds |
| 02/17/2005 | US20050038099 3-Amido-5-substituted pyrazole derivatives and related compounds useful as bradykinin B1 receptor antagonists to relieve adverse symptoms in mammals mediated, at least in part, by bradykinin B1 receptor including pain, inflammation, septic shock, scarring process |
| 02/17/2005 | US20050038095 Azolylbenzamides and analogues and their use for treating osteoporosis |
| 02/17/2005 | US20050038087 Derivatives of heterocycles with 5 members, their preparation and their use as medicaments |
| 02/17/2005 | US20050038084 Phenylalanine enamide derivatives |
| 02/17/2005 | US20050038072 Nitrogeneous cyclic ketone derivative, process for producing the same, and use |
| 02/17/2005 | US20050038069 Tumor necrosis factor antagonist; antiinflammatory agents; such as 2-Cyclopropyl-4-(3,5-dimethyl-4-pyridylmethoxy)-7-methoxy-3H-benzimidazole |
| 02/17/2005 | US20050038061 6-Aminomorphinane derivatives, method for production and use thereof |
| 02/17/2005 | US20050038055 Spiro tetrahydroquinazolines and dihydrocyclopentapyrimidines as CRF antagonists |
| 02/17/2005 | US20050038044 For drug resistance disease; side effect reduction; antiinflammatory agents; autoimmune disease |
| 02/17/2005 | US20050038034 Analgesics; neurodegenerative disorders; multiple sclerosis; Parkinson's disease; neuropathic pain |
| 02/17/2005 | US20050038029 Transferring, releasing nitric oxide; side effect reduction; using a compound containing nitrosos group |
| 02/17/2005 | US20050038023 Inhibitors of glycogen synthase kinase-3 (gsk-3) and aurora-2, both serine/threonine protein kinases; for treating diseases such as cancer, diabetes and alzheimer's disease |
| 02/17/2005 | US20050038014 5'-carbamoyl-1,1' biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
| 02/17/2005 | US20050038010 Substituted heterocyclic compounds and methods of use |
| 02/17/2005 | US20050037955 Bactericides; fungicides; isolated polypeptides; inflammatory bowel disorders; infections |
| 02/17/2005 | US20050037494 Using antisense agents to reduce and/or prevention genic expression associated with cardi-vascular complications; gene therapy |
| 02/17/2005 | US20050037464 Prokineticin polypeptides, related compositions and methods |
| 02/17/2005 | US20050037096 Dispersed solid-containing complex carbohydrate |
| 02/17/2005 | US20050037091 Composition comprising paracetamol and a bitterness masking component |
| 02/17/2005 | US20050037087 Microcapsular composition comprising core, including at least one active ingredient in combination with an oil or mixture of oils, wherein oils alone or in combination with active ingredient have specific gravity higher than that of water; microcapsules can be easily isolated by precipitation |
| 02/17/2005 | US20050037077 Absorption in upper part of gastrointestinal system; microcapsules coated with hydrophilic polymer such as Eudragit |
| 02/17/2005 | US20050037074 Treating adrenal dysfunction in a patient by administering a pharmaceutically effective amount of a combined glucocorticoid such as hydrocortisone and a delivery vehicle, wherein delivery vehicle provides for delayed and sustained release of glucorticoid; congenital adrenal hyperplasia |
| 02/17/2005 | US20050037028 Topical antiallergenic cream containing Asian longhorn beetle wastes; animal extracts |
| 02/17/2005 | US20050037024 Matrix metalloprotease inhibitor |
| 02/17/2005 | US20050037009 Methods and reagents for protease inhibition |
| 02/17/2005 | US20050037005 5c8 Antigen |
| 02/17/2005 | US20050037004 An aglycosylated antibody having a binding affinity for the CD3 antigen complex; antiinflammatory, antiarthritic agents |
| 02/17/2005 | US20050037003 Administering a soluble lymphotoxin- beta receptor, an antibody directed against LT- beta receptor, or an antibody directed against surface LT ligand with a carrier; multiple sclerosis, vision defects, psoriasis, inflammatory bowel disease; antidiabetic agents |
| 02/17/2005 | US20050036985 Use of biologically active hiv-1 tat, fragments or derivatives thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases |
| 02/17/2005 | US20050035267 Furnace mount and method of installation |
| 02/17/2005 | US20050035266 Furnace Mount and Method of Installation |
| 02/17/2005 | DE10334226A1 Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse Use of tyrosine kinase inhibitors for treating inflammatory processes |
| 02/17/2005 | DE10331980A1 Verwendung von Calpain zur Identifizierung von schmerzmodulierenden Verbindungen Use of calpain to identify pain-compounds |
| 02/17/2005 | CA2554566A1 Condensed pyramidine compounds as inhibitors of voltage-gated ion channels |
| 02/17/2005 | CA2535249A1 Spiro-substituted tetrahydroquinazolines as corticotropin releasing factor (cfr) antagonists |
| 02/17/2005 | CA2535066A1 Macrophage activation inhibitor |
| 02/17/2005 | CA2534905A1 Pyridyl piperazinyl ureas |
| 02/17/2005 | CA2534898A1 Bispecific antibodies for inducing apoptosis of tumor and diseased cells |
| 02/17/2005 | CA2534528A1 3-(indol-1-yl)-4-(indol-3-yl)-pyrrole-2,5-diones,3-(benzimidazol-1-yl)-4-(indol-3-yl)-pyrrole-2,5-diones, and 3-(indolin-1-yl)-4-(indol-3-yl)-pyrrole-2,5-diones; their preparationand use as modulators of apoptosis |
| 02/17/2005 | CA2534471A1 Method and apparatus for producing ultrafine drug particles |
| 02/17/2005 | CA2534415A1 Therapeutic delivery of carbon monoxide |
| 02/17/2005 | CA2533990A1 Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases |
| 02/16/2005 | EP1506962A2 Nitrogen-containing aromatic heterocycles |
| 02/16/2005 | EP1506958A1 Process for producing shogaol and intermediates for the synthesis thereof |
| 02/16/2005 | EP1506409A1 Assays for modulators of asparaginyl hydroxylase |
| 02/16/2005 | EP1506400A2 Pathway of rantes-mediated chemokine synthesis in astrocytes and methods of use therefor |
| 02/16/2005 | EP1506285A2 Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents |
| 02/16/2005 | EP1506214A1 6-11 bicyclic ketolide derivatives |
| 02/16/2005 | EP1506204A2 1-oxa-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof |
| 02/16/2005 | EP1506202A1 1-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the prepartion thereof |
| 02/16/2005 | EP1506198A1 5-ethylimidarotriazones |
| 02/16/2005 | EP1506196A2 Pyrazolopyrimidines |
| 02/16/2005 | EP1506192A1 Substituted pyrroline kinase inhibitors |
| 02/16/2005 | EP1506191A1 Benzoxazine and benzoxazinone substituted triazoles |
| 02/16/2005 | EP1506187A1 2-thio-substituted imidazole derivatives and their use in pharmaceutics |